Acute Leukemia Mini Panel Testing - $244 USD | Comprehensive Genetic Analysis for Leukemia Detection in USA
JAK3 Gene SCID Genetic Test USA | $500 USD | NGS DNA Testing for Severe Combined Immunodeficiency JAK3 Gene SCID Autosomal Recessive T Negative B Positive Type NGS Genetic DNA Test Original price was: $700.Current price is: $500.
BCR-ABL Variant Panel Test - $226 USD | Comprehensive Genetic Testing for Leukemia Detection in USA BCR-ABL Variant Panel Original price was: $300.Current price is: $226.
Sale!

Acute Leukemia Mini Panel – AML/ETO, INV16, PML/RARA, BCR/ABL, TEL/AML1, MLL, E2A

Original price was: $326.Current price is: $244.

-25%

The Acute Leukemia Mini Panel is a comprehensive genetic test that detects key chromosomal abnormalities associated with acute leukemia. Using advanced Real-Time PCR technology, this panel identifies seven critical genetic markers including AML/ETO, INV16, PML/RARA, BCR/ABL, TEL/AML1, MLL, and E2A rearrangements. This test is essential for accurate diagnosis, prognosis assessment, and treatment planning for patients with suspected or confirmed acute leukemia. Results are typically available within 5-6 days from bone marrow or peripheral blood samples. The test costs $244 USD with our current discount, providing affordable access to cutting-edge leukemia diagnostics. Early genetic detection enables personalized treatment approaches and improved patient outcomes.

Clinically Validated & Lab Certified

  • ISO-Accredited Laboratory, Ensuring Highest Standards
  • Trusted by Hospitals & Patients —Accredited Testing with Results
  • Direct Healthcare Provider Support + Comprehensive Reporting
Guaranteed Safe Checkout

Acute Leukemia Mini Panel – Comprehensive Genetic Testing for Leukemia Detection

Understanding Acute Leukemia Genetic Testing

The Acute Leukemia Mini Panel represents a breakthrough in molecular diagnostics for hematological malignancies. This advanced genetic screening test utilizes Real-Time PCR technology to detect specific chromosomal abnormalities that are critical for diagnosing and classifying acute leukemias. By identifying these genetic markers, healthcare providers can deliver more precise diagnoses and develop targeted treatment strategies.

What Does the Acute Leukemia Mini Panel Detect?

This comprehensive panel screens for seven essential genetic abnormalities associated with acute leukemia:

  • AML/ETO (t8;21) – Associated with acute myeloid leukemia with favorable prognosis
  • INV16 (CBFB-MYH11) – Core-binding factor leukemia with unique treatment response
  • PML/RARA (t15;17) – Acute promyelocytic leukemia requiring specific therapy
  • BCR/ABL (Philadelphia Chromosome) – Present in both ALL and CML cases
  • TEL/AML1 (ETV6-RUNX1) – Common in childhood ALL with good prognosis
  • MLL Rearrangements – Associated with aggressive leukemia subtypes
  • E2A Rearrangements – Important for B-cell ALL classification

Who Should Consider This Genetic Test?

This test is recommended for individuals presenting with:

  • Unexplained fatigue, weakness, or persistent fever
  • Frequent infections or unusual bleeding/bruising
  • Bone pain or joint discomfort
  • Enlarged lymph nodes, spleen, or liver
  • Abnormal complete blood count results
  • Family history of hematological malignancies
  • Suspected leukemia based on clinical presentation

Key Benefits of Acute Leukemia Genetic Testing

  • Accurate Diagnosis: Provides definitive genetic confirmation of leukemia subtypes
  • Prognostic Information: Helps predict disease course and treatment response
  • Treatment Guidance: Enables selection of targeted therapies based on genetic markers
  • Minimal Residual Disease Monitoring: Allows tracking of treatment effectiveness
  • Early Detection: Identifies genetic abnormalities before full disease manifestation

Understanding Your Test Results

Your results will indicate the presence or absence of specific genetic abnormalities. A positive result for any of the tested markers provides crucial information for:

  • Disease Classification: Determining the exact type of leukemia
  • Risk Stratification: Assessing disease aggressiveness and prognosis
  • Therapeutic Decisions: Guiding chemotherapy and targeted therapy choices
  • Monitoring Strategy: Establishing baseline for treatment response assessment

Negative results help rule out common genetic abnormalities and may suggest alternative diagnoses.

Test Information and Pricing

Test Component Details
Test Name Acute Leukemia Mini Panel – AML/ETO, INV16, PML/RARA, BCR/ABL, TEL/AML1, MLL, E2A
Discount Price $244 USD
Regular Price $326 USD
Turnaround Time 5-6 Days
Sample Type Bone marrow / Peripheral blood (Transport immediately)
Test Components EDTA Vacutainer (2ml)
Methodology Real Time PCR

Nationwide Testing Availability

We have diagnostic centers conveniently located across the United States, including major metropolitan areas such as New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our state-of-the-art facilities ensure consistent, high-quality testing standards nationwide.

Take Action for Your Health Today

Early genetic detection of leukemia can significantly impact treatment outcomes and survival rates. Don’t wait for symptoms to progress – proactive testing provides the information needed for timely intervention and personalized care strategies.

Ready to schedule your Acute Leukemia Mini Panel? Contact our genetic specialists today at +1(267) 388-9828 or book your appointment online. Our team is available to answer your questions and guide you through the testing process.

Note: This test requires a doctor’s prescription for diagnostic purposes. Prescription requirements do not apply for surgical clearance, pregnancy-related testing, or international travel documentation.

SKU: 569ff987c643 Category:

Related products